Levacecarnine

Drug Profile

Levacecarnine

Alternative Names: Acetyl-L-carnitine; ALC; Alcar; Branigen; L-acetylcarnitine; Nicetile; RO 447190; ST 200; ST 211HCl; Zibren

Latest Information Update: 09 Nov 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sigma-tau SpA
  • Developer Dong-A ST; GlaxoSmithKline; sigma-tau SpA; Tanabe Seiyaku
  • Class Antidementias; Neuroprotectants; Quaternary ammonium compounds; Small molecules
  • Mechanism of Action Carnitine acetyltransferase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease; Dementia; Diabetic neuropathies; Peripheral nervous system diseases
  • Discontinued Diabetic complications; Fatigue

Most Recent Events

  • 02 Nov 2016 Launched for Alzheimer's disease in South Korea (PO) before November 2016
  • 01 Oct 2007 Mitsubishi Pharma Corporation has merged with Tanabe Seiyaku to form Mitsubishi Tanabe Pharma Corporation
  • 20 Sep 2007 Levacecarnine licensed to Lee's Pharmaceutical in China and Hong Kong
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top